看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。' X9 ^8 f/ P0 f
c, {* G6 r5 d8 i( X8 T3 {7 }
& g# K. G5 O/ @, Q' @ G! E) U# pCurrently available feasibility data for possible combination strategies.
, s, G9 U( C3 E————————————————————————————————
3 t8 e0 `9 Q$ P+ t- FCombination Feasibility according to preliminary data + z( ?, Z, b9 R$ D
——————————————————————————————————
5 x! }: [7 ^9 i9 KBevacizumab + sorafenib Yes, reduced dose 6 f' B# ?% }# D0 A& E
Bevacizumab + sunitinib† No ' M8 w/ t% j2 _% [8 ]6 t! Q
Bevacizumab + temsirolimus Yes
4 I6 `& |; k2 h! \# iBevacizumab + everolimus Yes 6 `. {+ ^6 q& m2 o- c
Sorafenib + sunitinib ?
4 i$ F+ P1 V; W: ?; uSorafenib + temsirolimus Yes, reduced dose 3 D& G1 S- X& V
Sorafenib + everolimus Yes, reduced dose - Q9 g4 R5 c4 e, ~
Sunitinib + temsirolimus† No
6 ~- b$ X* z- J* ]5 z% {Sunitinib + everolimus ?
; {3 n& u! o$ N3 T( @) E& BTemsirolimus + everolimus ? 8 Y! H% ^; X/ w) _" Q+ }
————————————————————
; e- `# k0 S% d: g/ _†Led to US FDA warning.
. x( b8 G' a! Q$ z" }?: As yet unattempted combination.3 m- M B @* h/ }0 X' X+ z/ I% z
|